A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
← catalyst calendarNCT07795814 · readout ≤ 486 d
Sponsored by Edgewise Therapeutics, Inc. (industry) · EWTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
90estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-25 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure With Preserved Ejection Fraction
Interventions
- Drug: EDG-15400 25 mg
- Drug: Placebo to match EDG-15400 25 mg or 50 mg
- Drug: EDG-15400 50 mg
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured From baseline through study completion (up to 20 weeks)
Related
EWTX · their whole pipeline · Heart Failure readouts
EWTX's other studiesmost recently updated first
- A Study of EDG-15400 in Healthy Adults Phase 1 · Completed
- Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Phase 2 · Active, not recruiting
- Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy Phase 2 · Enrolling by invitation
- A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) Phase 2 · Active, not recruiting
- A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment Phase 1 · Completed
Permalink · EWTX's whole pipeline · Catalyst calendar · Every registered study · What changed